Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.25 0.12 −8.76%
Market cap
$16.1M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
5/9
Altman Z
−14.26
Beneish M
−3.39
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
29.54 20.48 101.89 113.19 250.61 38.45 17.31 16.52 1.02 5.25
Receivables
5.20 4.75 9.32 7.02 4.93 2.78 6.33 4.51 3.35 1.85
Inventory
5.45 11.12 22.89 29.76 12.39 3.32 3.44 1.07 1.69 1.80
Total current assets
45.39 39.49 140.12 157.30 272.41 46.79 28.26 23.03 7.14 10.74
Property, Plant, Equpment (Net)
14.85 19.22 23.35 18.03 10.32 4.91 1.95 1.78 3.01 4.05
Goodwill and Intangible Assets (Total)
4.35 9.71 33.97 118.43 83.00 8.65 — — — —
Long-term assets (Other)
2.69 3.15 7.83 2.81 0.75 0.10 — — — —
Total non-current assets
28.20 37.18 74.29 150.20 104.69 13.66 1.95 1.78 3.01 4.05
Total Assets
73.58 76.67 214.40 307.50 377.10 60.45 30.21 24.80 10.15 14.79
Notes Payable
9.98 20.36 69.80 — — — — — — —
Accounts Payable
5.59 6.96 10.38 12.53 10.77 2.93 2.70 1.35 2.30 0.79
Accrued Expenses
5.46 5.64 8.09 10.55 8.62 5.60 3.23 2.90 3.51 2.89
Current Part of Debt
— — — — — — 20.09 — 6.73 0.59
Current Part of Capital Lease
0.25 0.26 0.27 0.29 0.30 — — — — —
Current Revenue (Deferred)
— — — — — — — 0.27 0.21 0.45
Other current liabilities
0.97 1.13 9.32 10.25 0.68 0.42 0.36 0.27 3.90 4.65
Total current liabilities
22.94 37.34 100.03 35.88 21.84 8.95 26.37 4.52 16.65 9.36
Long Term Debt (Total)
3.48 3.54 3.59 3.62 3.64 16.33 — 9.03 — 6.05
Non-current Revenue (Deferred)
— — — — — — — — 0.14 0.24
Liabilities (Preferred Stock)
— — — — — — — — 43.01 25.42
Non-current Liabilities (Other)
0.25 0.27 11.04 13.10 9.21 0.10 0.23 1.11 0.57 0.98
Total non-current liabilities
6.22 3.95 18.22 22.22 18.14 16.42 0.23 10.14 43.72 32.68
Total liabilities
29.16 41.30 118.25 58.10 39.98 25.37 26.59 14.67 60.37 42.05
Additional Paid In Capital
764.03 728.57 677.34 599.23 553.75 178.75 106.19 82.90 4.04 3.64
Common Stock (Net)
0.00 — 0.01 0.00 0.03 0.02 0.00 0.00 0.00 0.00
Retained Earnings
(719.62) (693.22) (581.21) (348.71) (216.12) (143.68) (102.58) (72.76) (54.27) (30.90)
Common Equity (Total)
44.42 35.38 96.16 249.40 337.12 35.08 3.61 10.14 (50.23) (27.26)
Shareholders Equity (Total)
44.42 35.38 96.16 249.40 337.12 35.08 3.61 10.14 (50.23) (27.26)
Shareholders Equity and Liabilities (Total)
73.58 76.67 214.40 307.50 377.10 60.45 30.21 24.80 10.15 14.79
Shares (Common)
10.74 1.87 0.76 0.50 0.48 0.32 0.06 0.02 0.00 0.00
Shares (Preferred)
— — — — — — — — 0.20 —
Shareholders Equity (Tangible)
40.08 25.67 62.18 130.97 254.12 26.43 3.61 10.14 (50.23) (27.26)
Net Debt
(26.05) (16.94) (98.30) (109.57) (246.97) (22.12) 2.77 (7.49) 5.71 1.38
Total Debt
3.48 3.54 3.59 3.62 3.64 16.33 20.09 9.03 6.73 6.63

Fold the line items

In millions of $ except per-share values · columns are period end dates